CEA Industries Inc. Reports Fourth Quarter and Full Year 2023 Results
Louisville, Colorado, March 28, 2024 (GLOBE NEWSWIRE) — CEA Industries Inc. (NASDAQ: CEAD, CEADW) (“CEA Industries” or the “Company”), is […]
Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) […]
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted […]
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs […]
TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffirming Its Commitments to a Zero-Harm Culture and Carbon Neutrality
SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) — TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its […]
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
— Company to host call at 4:30pm today — NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, […]
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today […]
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 […]
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end […]
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering […]
